id: NEW:african_american_race_to_sud_medication_treatment_rate_oud
name: African-American Race â†’ SUD Medication Treatment Rate
from_node:
  node_id: NEW:african_american_race
  node_name: African-American Race
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: SUD Medication Treatment Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Structural racism creates differential access to healthcare services and quality of care'
- 'Step 2: Implicit bias among providers may lead to lower rates of AUD screening and pharmacotherapy
  recommendations for African-American women'
- 'Step 3: Historical medical mistrust due to systemic racism may affect treatment engagement and acceptance'
- 'Step 4: Reduced likelihood of receiving evidence-based pharmacotherapy for AUD among African-American
  women veterans'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Emmeline Taylor et al. 2019. "Receipt of pharmacotherapy for alcohol use disorder
    by justice-involved women in the Veterans Health Administration.." https://doi.org/10.1186/s13722-018-0129-x
  supporting_citations:
  - Additional citations require full-text access - abstract references racial disparities in treatment
  - Additional citations require full-text access - abstract references barriers to AUD treatment access
  - Additional citations require full-text access - abstract references patient factors in pharmacotherapy
    receipt
  doi: 10.1186/s13722-018-0129-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: African-American women veterans have 27% lower odds of receiving pharmacotherapy for AUD
  compared to non-African-American women veterans, demonstrating persistent racial disparities in evidence-based
  substance use treatment within the VHA system.
quantitative_effects:
  effect_size:
    value: 0.73
    type: odds_ratio
    ci_lower: 0.68
    ci_upper: 0.79
  sample_size: 10511
structural_competency:
  equity_implications: This finding demonstrates that structural racism operates within the VHA healthcare
    system despite its universal coverage model. Racial disparities in pharmacotherapy receipt cannot
    be attributed to insurance or access barriers, pointing to implicit bias, differential treatment recommendations,
    or systemic factors that disadvantage African-American women in receiving evidence-based AUD treatment.
    This disparity requires targeted interventions addressing provider bias and systemic barriers to equitable
    care.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.269682'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
